In 2016, in an effort to better focus business priorities, Fulgent Therapeutics separated into pure-play diagnostics and therapeutics companies Fulgent Genetics and Fulgent Pharma. Yesterday, after six years of honing their business models, publicly traded Fulgent Genetics announced it was acquiring Fulgent Pharma for $100 million to create a vertically…

Over the past two decades scientists have been working steadily to unravel the complex interplay of the microbiome, human health, and disease. Our understanding of the microbiome—or the community of microorganisms that reside in the human body—has been greatly advanced thanks to the improvements in next-generation sequencing techniques, with methods…

The University of Texas MD Anderson Cancer Center and Basel, Switzerland-based ARTIDIS AG announced today a research collaboration that will build clinical evidence of ARTIDIS’ atomic force microscopy (AFM) nanomechanical technology for the analysis of solid tumors. The collaboration efforts by MD Anderson and ARTIDIS researchers will evaluate the combination…

In a paper published in Nature Cell Biology, researchers at Sanford Burnham Prebys, led by Ze’ev Ronai, PhD, have shown for the first time that inhibiting a key metabolic enzyme selectively kills melanoma cells and stops tumor growth. “We found that melanoma is addicted to an enzyme called GCDH, or…

Electronic health records (EHRs) – systems that control all hospital data – have been around since the early 1970s. One of the first, the Health Evaluation thru Logical Processing (HELP) system, was developed by medical informatics pioneer Homer Warner at LDS Hospital, now Intermountain Healthcare, in Salt Lake City, Utah.…

Synthetic lethality-focused oncology biopharma Ideaya Biosciences announced earlier this week that is has selected the a potential-first-in-class Pol Theta Helicase development candidate (DC) for its collaboration with GlaxoSmithKline (GSK) to evaluate it as a combination therapy with GSK’s PARP inhibitor niraparib. Sold under the trade name Zejula, niraparib is indicated…

By Kenny Wong Kenny Wong Precision medicine is advancing quickly: In genomics, there are currently more than 160,000 testing products, with 30 new tests each day.1 Examples include: diagnostic testing to identify whether an individual has a specific genetic condition (e.g. cystic fibrosis); non-invasive prenatal screening to…

Artificial intelligence (AI)-enabled patient-centric oncology clinical trial enrollment company Massive Bio and AdhereTech, a smart device company that provides real-time data to help drive clinical decisions announced they will work together to develop digital health technology solutions. The partnership will focus on oral oncology therapies with the aim of providing…

Elevation Oncology’s drug candidate seribantumab, currently being evaluated is a Phase II study, has received FDA Fast Track designation for tumor-agnostic  treatment of advanced cancers harboring an NRG1 gene fusion. Seribantumab is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3). HER3 is…

Knowing whether chemotherapy has been successful in treating cancer is always critical, especially in the case of bladder cancer in which treatment failure often leads to radical cystectomy, or bladder removal surgery. Experienced physicians are able to make that determination. Now, a new machine learning tool has been created to…

Sponsored content brought to you by NeoGenomics has added a new next-generation sequencing (NGS) assay to its lineup of oncology tests: RaDaR™. For insight into this new technology and how it’s set to transform care for cancer patients, Inside Precision Medicine turned to the Chief Medical Officer of Clinical Services…

A study including data from more than 70,000 individuals shows that the chance of genetic variants labelled ‘pathogenic’ actually causing disease is low, although there is considerable variation between individual variants. Many people now undergo tests to look for genetic mutations that may increase a person’s risk for disease such…

Growing evidence that precision medicine would save lives is what prompted each of the health systems covered in this article to adopt an aggressive program early.  “This means improving care for our patients,” says Konstantinos N. Lazaridis, M.D., of Mayo Clinic. “It gives us more specific information about what causes…

A monoclonal antibody (MAB) developed by scientists at University College London (UCL) allows more effective delivery of targeted cancer treatments in mice by improving tumor vascular function. The findings, published in the journal MED, are the first to demonstrate that inhibiting the activity of LRG1, a protein produced in many tumorous…

New research led by investigators at MIT, has demonstrated that a patient’s own live tumor cells, damaged by chemotherapy, may also augment antitumor immunity. The results suggest these live cell adjuvants may enhance the effectiveness of immune checkpoint blockade (ICB) in tumors that wouldn’t normally respond to such treatment alone.…